Fingolimod Phosphate Attenuates Oligomeric Amyloid β-Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Doi, Yukiko ^a   Takeuchi, Hideyuki ^a   Horiuchi, Hiroshi ^a   Hanyu, Taketo ^a   Kawanokuchi, Jun ^a   Jin, Shijie ^a   Parajuli, Bijay ^a   Sonobe, Yoshifumi ^a   Mizuno, Tetsuya ^a   Suzumura, Akio ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; FINGOLIMOD PHOSPHATE; FTY 720P; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DRUG MECHANISM; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOPROTECTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; ORGANOPHOSPHATES; PROTEIN MULTIMERIZATION; RECEPTOR, TRKB; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84876095698     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061988     Document Type: Article

References (44)

1. Selkoe DJ, (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192: 106-113.
2. Walsh DM, Teplow DB, (2012) Alzheimer's disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 107: 101-124.
3. Deshpande A, Mina E, Glabe C, Busciglio J, (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26: 6011-6018.
4. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, et al. (2009) Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol 175: 2121-2132.
5. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, et al. (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282: 11590-11601.
6. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, et al. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 883-897.
7. Chun J, Hartung HP, (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91-101.
8. Cohen JA, Chun J, (2011) Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 69: 759-777.
9. Pelletier D, Hafler DA, (2012) Fingolimod for multiple sclerosis. N Engl J Med 366: 339-347.
10. Adachi K, Kohara T, Nakao N, Arita M, Chiba K, et al. (1995) Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem 5: 853-856.
11. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349.
12. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360.
13. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, et al. (2000) FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 164: 5761-5770.
14. Brinkmann V, (2007) Sphingosine 1-phosphate receptors in health and disease: mechanistic insight from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84-105.
15. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457.
16. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, et al. (2008) Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117: 77-93.
17. Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, et al. (2010) Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 176: 2682-2694.
18. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, et al. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108: 751-756.
19. Noda H, Takeuchi H, Mizuno T, Suzumura A (2013) Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol.
20. Harada J, Foley M, Moskowitz MA, Waeber C, (2004) Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 88: 1026-1039.
21. Kimura A, Ohmori T, Ohkawa R, Madoiwa S, Mimuro J, et al. (2007) Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25: 115-124.
22. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, et al. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277: 32046-32053.
23. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, et al. (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280: 10444-10454.
24. Mizuno T, Doi Y, Mizoguchi H, Jin S, Noda M, et al. (2011) Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-beta neurotoxicity. Am J Pathol 179: 2016-2027.
25. Manelli AM, Bulfinch LC, Sullivan PM, LaDu MJ, (2007) Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging 28: 1139-1147.
26. Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, et al. (1991) The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 65: 895-903.
27. Osinde M, Mullershausen F, Dev KK, (2007) Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52: 1210-1218.
28. Kaneider NC, Lindner J, Feistritzer C, Sturn DH, Mosheimer BA, et al. (2004) The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB J 18: 1309-1311.
29. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S, (1997) Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 17: 2295-2313.
30. Yan Q, Radeke MJ, Matheson CR, Talvenheimo J, Welcher AA, et al. (1997) Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J Comp Neurol 378: 135-157.
31. Yan Q, Rosenfeld RD, Matheson CR, Hawkins N, Lopez OT, et al. (1997) Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience 78: 431-448.
32. Drake CT, Milner TA, Patterson SL, (1999) Ultrastructural localization of full-length trkB immunoreactivity in rat hippocampus suggests multiple roles in modulating activity-dependent synaptic plasticity. J Neurosci 19: 8009-8026.
33. Huang EJ, Reichardt LF, (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677-736.
34. Yoshii A, Constantine-Paton M, (2010) Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 70: 304-322.
35. Kemppainen S, Rantamaki T, Jeronimo-Santos A, Lavasseur G, Autio H, et al. (2012) Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging 33: 1122 e1123-1139.
36. Lu Y, Christian K, Lu B, (2008) BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 89: 312-323.
37. Mizuno M, Yamada K, He J, Nakajima A, Nabeshima T, (2003) Involvement of BDNF receptor TrkB in spatial memory formation. Learn Mem 10: 108-115.
38. Rex CS, Lin CY, Kramar EA, Chen LY, Gall CM, et al. (2007) Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J Neurosci 27: 3017-3029.
39. Minichiello L, (2009) TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 10: 850-860.
40. Koponen E, Voikar V, Riekki R, Saarelainen T, Rauramaa T, et al. (2004) Transgenic mice overexpressing the full-length neurotrophin receptor trkB exhibit increased activation of the trkB-PLCgamma pathway, reduced anxiety, and facilitated learning. Mol Cell Neurosci 26: 166-181.
41. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, et al. (1999) BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58: 729-739.
42. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, et al. (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7: 695-702.
43. Norimatsu Y, Ohmori T, Kimura A, Madoiwa S, Mimuro J, et al. (2012) FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms. Am J Pathol 180: 1625-1635.
44. Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, et al. (2012) Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 109: 14230-14235.